Physician profile
John Bray
NPI 1669463899
$1,525.34
in general payments reported to CMS, 2019-2025
15 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $125 · 2021: $33.93 · 2022: $199 · 2023: $273 · 2024: $202 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.07 |
| Education | $128.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $494.11 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $224.64 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Sunovion Pharmaceuticals INC. | $194.01 | 2019-2020 | |
| Blueprint Medicines Corporation | $95.38 | 2023-2024 | Ayvakit |
| Pfizer INC. | $94.94 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $94.66 | 2025 | Dupixent |
| Csl Behring | $90.21 | 2019-2025 | Hizentra, Haegarda |
| Genentech USA, INC. | $61.38 | 2023-2024 | Xolair |
| Amgen INC. | $34.00 | 2025 | |
| Inspire Medical Systems, INC. | $32.36 | 2025 | Inspire |
| Harmony Biosciences LLC | $30.39 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.83 | 2022 | |
| Biocryst US Sales Co., LLC | $18.42 | 2023 | Orladeyo |
| Alkermes, INC. | $18.38 | 2024 | Vivitrol |
| Merck Sharp & Dohme LLC | $17.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.